prostate-specific antigen (PSA) velocity
Jump to navigation
Jump to search
Reference interval
Principle
- rate of change in serum PSA values
Clinical significance
- biopsy on the basis of a PSA velocity > 0.35 ng/mL/yr as some current guidelines suggest would lead to large numbers of additional, unnecessary procedures
- optimal predictive PSA velocity* of 0.44 ng/mL/year in Black patients & 1.18 ng/mL/year in non-Hispanic whites
- optimal PSA velocity threshold for development of metastases is 1.77 ng/mL/year[2]
* predictive value for progression of active surveillance grade 1 prostate cancer to stage 2 or 3
More general terms
Additional terms
References
- ↑ 1.0 1.1 Vickers AJ et al An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection JNCI J Natl Cancer Inst (2011), February 24, 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21350221 <Internet> http://jnci.oxfordjournals.org/content/early/2011/02/24/jnci.djr028.abstract
Yao SL and Lu-Yao GL The Science and Art of Prostate Cancer Screening JNCI J Natl Cancer Inst (2011), February 24, 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21350220 <Internet> http://jnci.oxfordjournals.org/content/early/2011/02/24/jnci.djr047.full - ↑ 2.0 2.1 Nelson TJ et al. Association of prostate-specific antigen velocity with clinical progression among African American and non-Hispanic white men treated for low-risk prostate cancer with active surveillance. JAMA Netw Open 2021 May 17; 4:e219452. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33999164 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779928
Nyame YA, Porter MP. Prostate-specific antigen screening and active surveillance for high-risk individuals. JAMA Netw Open 2021 May 17; 4:e219711. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33999169 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779933